Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Clinical Trial ID NCT02381314

Rank	Title	Journal	Year	PubWeight™‹?›
1	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.	Sci Transl Med	2016	2.16
2	Combination cancer immunotherapies tailored to the tumour microenvironment.	Nat Rev Clin Oncol	2015	1.54
3	The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.	Ann Transl Med	2016	0.93
4	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.	Cancers (Basel)	2015	0.90
5	Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.	Cancer Biol Med	2015	0.80
6	Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.	Clin Cancer Res	2016	0.76
7	Immune Therapy for Prostate Cancer.	Cancer J	2016	0.76
8	Immunotherapy in genitourinary malignancies.	Curr Opin Urol	2016	0.75
9	Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.	World J Gastroenterol	2016	0.75